Page 112 - ITPS-7-3

INNOSC Theranostics and
Pharmacological Sciences Alpha-2A receptor agonist and addiction

105. Thanos PK, Hamilton J, O’Rourke JR, et al. Dopamine D2 gene 115. McLaughlin T, Febo M, Badgaiyan RD, et al. KB220Z™ a
expression interacts with environmental enrichment to impact pro-dopamine regulator associated with the protracted,
lifespan and behavior. Oncotarget. 2016;7(15):19111-19123. alleviation of terrifying lucid dreams. Can we infer
neuroplasticity-induced changes in the reward circuit? J
doi: 10.18632/oncotarget.8088
Reward Defic Syndr Addict Sci. 2016;2(1):3-13.
106. Thanos PK, Stamos J, Robison LS, et al. Daily treadmill
exercise attenuates cocaine cue-induced reinstatement and doi: 10.17756/jrdsas.2016-022
cocaine induced locomotor response but increases cocaine- 116. McLaughlin T, Han D, Nicholson J, et al. Improvement of
primed reinstatement. Behav Brain Res. 2013;239:8-14. long-term memory access with a pro-dopamine regulator
in an elderly male: Are we targeting dopamine tone? J Syst
doi: 10.1016/j.bbr.2012.10.035
Integr Neurosci. 2017;3(3).
107. Rahman N, Mihalkovic A, Geary O, Haffey R, Hamilton J, doi: 10.15761/JSIN.1000165
Thanos PK. Chronic aerobic exercise: Autoradiographic
assessment of GABA(a) and mu-opioid receptor binding in 117. Blum K, Gondré-Lewis MC, Modestino EJ, et al.
adult rats. Pharmacol Biochem Behav. 2020;196:172980. Understanding the scientific basis of post-traumatic stress
disorder (PTSD): Precision behavioral management overrides
doi: 10.1016/j.pbb.2020.172980
stigmatization. Mol Neurobiol. 2019;56(11):7836-7850.
108. Blum K, Oscar-Berman M, Dinubile N, et al. Coupling doi: 10.1007/s12035-019-1600-8
genetic addiction risk score (GARS) with electrotherapy:
Fighting iatrogenic opioid dependence. J Addict Res Ther. 118. Blum K, Marcelo F, Dushaj K, Fried L, Badgaiyan RD.
2013;4(163):1000163. “Pro-dopamine regulation (KB220Z™ )” as a long-term
therapeutic modality to overcome reduced resting state
doi: 10.4172/2155-6105.1000163 dopamine tone in opioid/opioid epidemic in America. J Syst
109. Blum K, Oscar-Berman M, Femino J, et al. Withdrawal from Integr Neurosci. 2016;2(3):162-165.
buprenorphine/naloxone and maintenance with a natural doi: 10.15761/JSIN.1000129
dopaminergic agonist: A cautionary note. J Addict Res Ther.
2013;4(2). 119. Blum K, Downs BW, Dushaj K, et al. The benefits of
customized dna directed nutrition to balance the brain
doi: 10.4172/2155-6105.1000146 reward circuitry and reduce addictive behaviors. Precis Med
110. Blum K, Badgaiyan RD, Agan G, et al. Molecular genetic (Bangalore). 2016;1(1):18-33.
testing in reward deficiency syndrome (RDS): Facts and 120. Solanki N, Abijo T, Galvao C, Darius P, Blum K, Gondré-
fiction. J Reward Defic Syndr. 2015;1(1):65-68. Lewis MC. Administration of a putative pro-dopamine
doi: 10.17756/jrds.2015-009 regulator, a neuronutrient, mitigates alcohol intake in
alcohol-preferring rats. Behav Brain Res. 2020;385:112563.
111. Blum K, Thanos PK, Wang GJ, et al. The food and drug
addiction epidemic: Targeting dopamine homeostasis. Curr doi: 10.1016/j.bbr.2020.112563
Pharm Des. 2018;23(39):6050-6061. 121. Steinberg B, Blum K, McLaughlin T, et al. Low-resolution
doi: 10.2174/1381612823666170823101713 electromagnetic tomography (LORETA) of changed
brain function provoked by pro-dopamine regulator
112. Blum K, Bowirrat A, Baron D, et al. Biotechnical (KB220z) in one adult ADHD case. Open J Clin Med Case
development of genetic addiction risk score (GARS) and Rep. 2016;2(11):1121.
selective evidence for inclusion of polymorphic allelic risk
in substance use disorder (SUD). J Syst Integr Neurosci. 122. Bruijnzeel AW, Marcinkiewcz C, Isaac S, et al. The
2020;6(2). effects of buprenorphine on fentanyl withdrawal in rats.
Psychopharmacology (Berl). 2007;191(4):931-941.
doi: 10.15761/JSIN.1000221
doi: 10.1007/s00213-006-0670-2
113. Fried L, Modestino EJ, Siwicki D, et al. Hypodopaminergia
and “precision behavioral management” (PBM): It is 123. Dackis C, O’Brien C. Neurobiology of addiction:
a generational family affair. Curr Pharm Biotechnol. Treatment and public policy ramifications. Nat Neurosci.
2020;21(6):528-541. 2005;8(11):1431-1436.
doi: 10.1038/nn1105-1431
doi: 10.2174/1389201021666191210112108
114. McLaughlin T, Blum K, Steinberg B, et al. Pro-dopamine 124. O’Brien CP. Anti-craving medications for relapse prevention:
regulator, KB220Z, attenuates hoarding and shopping A possible new class of psychoactive medications. Am J
behavior in a female, diagnosed with SUD and ADHD. Psychiatry. 2005;162(8):1423-1431.
J Behav Addict. 2018;7(1):192-203. doi: 10.1176/appi.ajp.162.8.1423
doi: 10.1556/2006.6.2017.081 125. Heidbreder CA, Hagan JJ. Novel pharmacotherapeutic

Volume 7 Issue 3 (2024) 18 doi: 10.36922/itps.1918